Valuation: Alvotech

Market Cap 1.11B 971M 904M 832M 1.56B 106B 1.59B 10.73B 4.2B 52.42B 4.15B 4.06B 181B P/E 2026 *
8.41x
P/E 2027 * 7.18x
Enterprise Value 2.15B 1.89B 1.76B 1.62B 3.04B 206B 3.09B 20.89B 8.18B 102B 8.09B 7.91B 353B EV / Sales 2026 *
3.26x
EV / Sales 2027 * 2.73x
Free-Float
45.12%
Yield 2026 *
-
Yield 2027 * -
1 day+0.65%
1 week-12.50%
Current month-16.53%
1 month-16.30%
3 months-12.50%
6 months-41.78%
Current year-39.96%
1 week 3.04
Extreme 3.04
3.29
1 month 3.04
Extreme 3.04
3.95
Current year 2.94
Extreme 2.94
5.58
1 year 2.94
Extreme 2.94
9.73
3 years 2.94
Extreme 2.94
18
5 years 2.94
Extreme 2.94
18
10 years 2.94
Extreme 2.94
18
Manager TitleAgeSince
Chief Executive Officer 55 01/03/2026
Director of Finance/CFO 48 10/07/2025
Chief Tech/Sci/R&D Officer - 01/01/2023
Director TitleAgeSince
Chairman 56 01/01/2019
Director/Board Member 64 01/01/2019
Director/Board Member 58 01/01/2019
Date Insider Type Main position Quantity % Market Cap.
4/1/26 A Free

Chief Executive Officer

117,271 0.0355%
4/1/26 A Buy

Founder

318,000 0.0963%
4/1/26 A Sell

Founder

318,000 0.0963%
Change 5-day change 1-year change 3-year change Capi.($)
+0.65%-12.50%-68.60%-68.57% 1.11B
+0.55%+4.70%-3.21%+11.16% 47.88B
-2.24%+0.31%+393.45%+615.13% 39.09B
+1.40%+3.69%+12.21%+46.79% 36.75B
+13.94%+20.49%+22.85%+7.42% 40.55B
-0.73%+3.38%+4.94%+41.45% 27.96B
+0.40%-0.30% - - 16.77B
-3.12%+7.39%+26.03%+124.08% 15.94B
-1.28%-4.31%+1.56%+7.93% 13.55B
+6.79%+8.17%-4.97%-28.52% 13.81B
Average +1.61%+2.92%+42.70%+84.10% 25.34B
Weighted average by Cap. +2.21%+4.96%+71.97%+124.14%

Financials

2026 *2027 *
Net sales 661M 580M 540M 497M 931M 63.13B 947M 6.41B 2.51B 31.31B 2.48B 2.43B 108B 800M 702M 654M 601M 1.13B 76.41B 1.15B 7.75B 3.03B 37.89B 3B 2.94B 131B
Net income 165M 144M 135M 124M 232M 15.72B 236M 1.6B 625M 7.8B 618M 605M 26.94B 134M 118M 110M 101M 189M 12.84B 193M 1.3B 510M 6.37B 504M 494M 22B
Net Debt 1.05B 920M 857M 788M 1.48B 100B 1.5B 10.16B 3.98B 49.66B 3.94B 3.85B 172B 1.08B 948M 883M 812M 1.52B 103B 1.55B 10.48B 4.1B 51.21B 4.06B 3.97B 177B
Logo Alvotech
Alvotech SA is a biotechnology company. The Company is focused on the development and manufacture of biosimilar medicines for patients globally. It is engaged in developing a pipeline of monoclonal antibodies that target a variety of therapeutic areas including inflammatory diseases, oncology, and ophthalmology. The Company’s pipeline contains eight biosimilar candidates aimed at treating autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer. Its products pipeline includes AVT02, AVT04, AVT23, AVT03, AVT05, AVT06, AVT16, and AVT33. Its AVT02 is a monoclonal antibody and a biosimilar to Humira (adalimumab). AVT04 is a monoclonal antibody and a biosimilar candidate to Stelara (ustekinumab). It has formed a network of strategic commercial partnerships to provide global reach and leverage expertise in markets that include the United States (U.S.), Europe, Japan, China, and other Asian countries and large parts of South America, Africa, and the Middle East.
Employees
1,279
Date Price Change Volume
28/07/26 $3.100 +0.65% 330,587
27/07/26 $3.080 +0.65% 397,899
24/07/26 $3.060 -3.77% 588,655
23/07/26 $3.180 -0.31% 1,179,396
22/07/26 $3.190 -9.38% 1,476,739
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
5
Last Close Price
3.100USD
Average target price
6.500USD
Spread / Average Target
+109.68%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ALVO Stock